Table 2 Medication usage with the CARRAnet JDM cohort (N=102)
| Â | Current use | Previous use | Never used | Missing |
|---|---|---|---|---|
All corticosteroids | 51 (52.6%) | 46 (47.4%) | 0 (0.0%) | 5 |
Daily corticosteroids | 50 (51.5%) | 46 (47.4%) | 1 (1.1%) | 5 |
Methotrexate | 65 (68.4%) | 27 (28.4%) | 3 (3.2%) | 7 |
Pulse corticosteroids | 4 (4.2%) | 48 (50.5%) | 43 (45.3%) | 7 |
Hydroxychlorquine | 39 (41.1%) | 17 (17.9%) | 39 (41.1%) | 7 |
Intravenous gammaglobulin | 24 (24.5%) | 24 (24.5%) | 50 (51.0%) | 4 |
Mycophenolate mofetil | 13 (13.7%) | 5 (5.3%) | 77 (81.1%) | 7 |
Cyclosporine A | 4 (4.2%) | 5 (5.3%) | 86 (90.5%) | 7 |
Rituximab | 1 (1.0%) | 7 (7.1%) | 90 (91.8%) | 4 |
Cyclophosphamide | 0 (0.0%) | 2 (2.1%) | 93 (97.9%) | 7 |